Fig. 6

KIAA1199 gene expression and plasma levels correlate with obesity and insulin resistance phenotype in humans. Plasma KIAA1199 was measured in a cohort of 56 women that were grouped by body mass index (BMI) and metabolic syndrome as lean (LE, n = 12), overweight (OV, n = 10), obese (OB, n = 16) or obese with metabolic syndrome (MS, n = 16). Plasma KIAA1199 is correlated with fat free mass in OV, OB and MS patients (a), total cholesterol (b) and triglycerides (c) in all the patients. KIAA1199 mRNA levels in abdominal VAT correlated with free fatty acid (d), glycerol (e) in all patients and leptin mRNA levels in OV, OB and MS groups (f). g Plasma KIAA1199 correlated with fasting blood glucose in all patients. h KIAA1199 mRNA levels in VAT correlated with the values of homeostatic model assessment-insulin resistance (HOMA-R) in all patients. i Comparison of KIAA1199 gene expression in VAT in LE, OV, OB and MS four groups’ patients. j Gene expression levels of KIAA1199 curated from public databases GOI_GSE20950. The KIAA1199 gene expression in fat tissues from obese patients that are either insulin resistant (n = 20) or insulin sensitive (n = 19) were compared. k UK Biobank based summary statistics of the association between human sequence variations and whole-body fat mass (n = 7 637) for chromosome 15. Zoom in to bp 80 280 001–81 990 000 (hg19) surrounding the KIAA1199 locus. The dotted line indicates a P-value of 5 × 10⁻⁸. Analysis of Pearson two-tailed correlation test (r = correlation coefficient) was performed using GraphPad Prism software (a–h). Statistical difference was determined by one-way ANOVA with Dunnett’s multiple tests (i) or two-tailed unpaired Student’s t-test between two groups (j). The number of independent donors (n) in each correlation analysis is described in the results section and in each figure. *P < 0.05, **P < 0.01 and ***P < 0.001